Overview

Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

Phase:

Phase 4

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Remifentanil